Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Medicale (MCLE) EBITDA (2020 - 2025)

Historic EBITDA for Medicale (MCLE) over the last 6 years, with Q3 2025 value amounting to -$8654.0.

  • Medicale's EBITDA rose 4420.01% to -$8654.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$34007.0, marking a year-over-year increase of 3783.79%. This contributed to the annual value of -$33493.0 for FY2025, which is 3877.75% up from last year.
  • Per Medicale's latest filing, its EBITDA stood at -$8654.0 for Q3 2025, which was up 4420.01% from -$3575.0 recorded in Q2 2025.
  • In the past 5 years, Medicale's EBITDA ranged from a high of -$3575.0 in Q2 2025 and a low of -$19307.0 during Q4 2023
  • For the 5-year period, Medicale's EBITDA averaged around -$9747.5, with its median value being -$8595.5 (2023).
  • Its EBITDA has fluctuated over the past 5 years, first crashed by 12156.3% in 2023, then soared by 6150.95% in 2025.
  • Over the past 5 years, Medicale's EBITDA (Quarter) stood at -$18096.0 in 2021, then soared by 51.85% to -$8714.0 in 2022, then plummeted by 121.56% to -$19307.0 in 2023, then rose by 19.67% to -$15509.0 in 2024, then skyrocketed by 44.2% to -$8654.0 in 2025.
  • Its last three reported values are -$8654.0 in Q3 2025, -$3575.0 for Q2 2025, and -$6269.0 during Q1 2025.